文献速递妇科产科

GOG 244:妇科癌症患者淋巴水肿的发生率与危险因素

GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.
PubMed 文献 · Gynecol Oncol · 2019-12-16

GOG 244 研究纳入接受淋巴结清扫的子宫内膜癌、宫颈癌或外阴癌患者,术前及术后多个时间点测量腿围计算肢体体积变化(LVC),淋巴水肿定义为 LVC≥10%。可评估 734 例子宫内膜癌、138 例宫颈癌和 42 例外阴癌患者,LVC≥10% 发生率分别为 34%、35% 和 43%,峰值出现在术后 4-6 周评估时。逻辑回归显示高龄(>65 岁)风险降低(p=0.0467),子宫内膜癌队列探索性分析显示淋巴结计数>8 风险增加(p=0.033),未发现放疗或其他因素与淋巴水肿相关。

要点

  • 子宫内膜癌、宫颈癌、外阴癌患者淋巴结清扫后 LVC≥10% 发生率分别为 34%、35%、43%。
  • 淋巴水肿发生率峰值出现在术后 4-6 周评估时。
  • 高龄(>65 岁)与淋巴水肿风险降低相关(p=0.0467)。

核心结论

  • 在妇科癌症中,年龄大于 65 岁者 LVC 降低,但子宫内膜癌队列中淋巴结计数大于 8 者 LVC 增加,未发现放疗或其他因素与淋巴水肿相关。

研究设计与样本

  • GOG 244 研究为前瞻性队列研究,纳入接受淋巴结清扫的子宫内膜癌、宫颈癌或外阴癌患者,术前及术后 4-6 周、3、6、9、12、18、24 个月测量腿围计算 LVC。
  • 共纳入 1054 例,140 例因测量不足或不符合入选标准不可评估,最终可评估 734 例子宫内膜癌、138 例宫颈癌和 42 例外阴癌患者。
  • 淋巴水肿定义为肢体体积变化(LVC)≥10%,分级为轻度 10-19%、中度 20-40%、重度 >40%。

主要发现

  • LVC≥10% 发生率在子宫内膜癌组为 34%(n=247),宫颈癌组为 35%(n=48),外阴癌组为 43%(n=18)。
  • 淋巴水肿发生率峰值出现在术后 4-6 周评估时。
  • 逻辑回归分析显示高龄与淋巴水肿风险降低相关(p=0.0467)。
  • 子宫内膜癌队列探索性分析显示淋巴结计数>8 与淋巴水肿风险增加相关(p=0.033)。
  • 未发现放疗或其他因素与淋巴水肿相关。

关键数值与推荐

  • 淋巴水肿定义为肢体体积变化(LVC)≥10%。
  • 轻度淋巴水肿:LVC 10-19%;中度:LVC 20-40%;重度:LVC >40%。

临床怎么用

  • 对于接受淋巴结清扫的妇科癌症患者,应在术后 4-6 周及后续多个时间点监测肢体体积变化以评估淋巴水肿。
  • 年龄大于 65 岁者淋巴水肿风险较低,淋巴结计数大于 8 的子宫内膜癌患者风险较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the incidence and risk factors for lymphedema associated with surgery for gynecologic malignancies on GOG study 244. METHODS: Women undergoing a lymph node dissection for endometrial, cervical, or vulvar cancer were eligible for enrollment. Leg volume was calculated from measurements at 10-cm intervals starting 10 cm above the bottom of the heel to the inguinal crease. Measurements were obtained preoperatively and postoperatively at 4-6 weeks, and at 3-, 6-, 9-, 12-, 18-, and 24- months. Lymphedema was defined as a limb volume change (LVC) ≥10% from baseline and categorized as mild: 10-19% LVC; moderate: 20-40% LVC; or severe: >40% LVC. Risk factors associated with lymphedema were also analyzed. RESULTS: Of 1054 women enrolled on study, 140 were inevaluable due to inadequate measurements or eligibility criteria. This left 734 endometrial, 138 cervical, and 42 vulvar patients evaluable for LVC assessment. Median age was 61 years (range, 28-91) in the endometrial, 44 years (range, 25-83) in the cervical, and 58 years (range, 35-88) in the vulvar group. The incidence of LVC ≥10% was 34% (n = 247), 35% (n = 48), and 43% (n = 18), respectively. The peak incidence of lymphedema was at the 4-6 week assessment. Logistic regression analysis showed a decreased risk with advanced age (p = 0.0467). An exploratory analysis in the endometrial cohort showed an increased risk with a node count >8 (p = 0.033). CONCLUSIONS: For a gynecologic cancer, LVC decreased with age greater than 65, but increased with a lymph node count greater than 8 in the endometrial cohort. There was no association with radiation or other risk factors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Carlson JW, Kauderer J, Hutson A, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol. 2019. PMID: 31837831. doi:10.1016/j.ygyno.2019.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。